Mortality in patients with kidney failure has been found to be 23% lower among those treated with high dose haemodiafiltration compared to those treated with high flux haemodialysis, according to new research from the CONVINCE consortium led by University Medical Center Utrecht.
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer. Findings from the global FRESCO-2 trial, published today in The Lancet, were first presented at the European Society for Medical Oncology (ESMO) Congress 2022.
A new clinical trial run by Howard University, the University of Illinois Chicago and the University of Miami Miller School of Medicine will partner with community organizations and sites to bring life-saving care closer to a highly vulnerable population – Black people with opioid use disorder.
Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a clinical trial funded by the National Eye Institute (NEI).
Howard Colman, MD, PhD, was recently featured as an author on a publication in Nature Medicine describing the results of a recent clinical trial – a breakthrough in glioblastoma treatment with the help of a modified cold virus injected directly into the tumor. When combined with an immunotherapy drug, the authors observed a subset of patients that appeared to be living longer as a result of this therapy.
In a new study published in The Lancet Infectious Diseases, University of Minnesota researchers found that metformin, a drug commonly used to treat diabetes, prevents the development of long COVID.
As more families consider bariatric surgery a viable option to treat their child’s obesity, it is important to stay up-to-date on the latest research on weight loss. You can find the latest research on bariatric surgery and other weight loss options in the Weight Loss channel on Newswise, where journalists can find story ideas on this trending topic.
This case study by Dana-Farber gives evidence-based guidance for how to navigate decision-making for individual patients with metastatic hormone-sensitive prostate cancer.
Researchers presenting preliminary data from a clinical trial aimed at discovering a cure for sickle cell disease reveal positive results among its first patients. Sickle cell disease, a genetic blood disorder, is a painful and debilitating condition for which there are few approved therapies.
In a recent commentary, University of Illinois Chicago researchers and colleagues explain how embedded pragmatic clinical trials, or ePCTs, which test the effectiveness of medical interventions in real-world settings, potentially leave out people who are from underrepresented and underserved groups.
An automated, bilingual, computerized alcohol screening and intervention health tool is effective in reducing alcohol use among Latino emergency department patients in the U.S., according to a study led by the University of California, Irvine. “This is the first bilingual, large-scale, emergency department-based, randomized clinical trial of its kind in the country focused on English- and Spanish-speaking Latino participants,” said lead author Dr.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
The American Society for Radiation Oncology (ASTRO) Gastrointestinal Cancers Resource Panel issued a statement today on the PROSPECT clinical trial for patients with locally advanced rectal cancer. The statement clarifies that the trial did not explicitly conclude that radiation therapy should be omitted, contrary to many news reports, but rather that patients now have an additional treatment option to consider in discussions with their care team.
Treatment efficacy for a broad range of chronic diseases does not differ depending on patients’ comorbidities, according to a new study publishing June 6th in the open access journal PLOS Medicine by David McAllister of the University of Glasgow, UK, and colleagues.
MEDSIR announced today the results of the PALMIRA trial. This randomized phase 2 study evaluated the safety and efficacy of palbociclib maintenance in combination with second-line endocrine therapy in patients with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer who had showed a confirmed progressive disease on first-line palbociclib plus endocrine therapy-based treatment after having achieved clinical benefit to this regimen.
A randomized controlled clinical trial of a device shows promise for quieting the phantom noises of tinnitus.
A new study from researchers at Sanford Burnham Prebys and Eli Lilly and Company describes the science behind an autoimmune disease treatment in a Phase 2 clinical trial.
Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (axi-cel) when compared to the current standard-of-care chemoimmunotherapy, according to results of the Phase III ZUMA-7 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
Three clinical trials led by MD Anderson researchers showed positive results with the targeted therapy erdafitinib for patients with FGFR-altered tumors. The data were presented at the 2023 ASCO Annual Meeting.
In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit in several tumor types. These data from an interim analysis of the Phase II DESTINY-PanTumor02 study, led by The University of Texas MD Anderson Cancer Center, were presented today at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening. The finding suggests a possible new treatment option for people with the slow-growing but deadly brain tumor.
MEDSIR announced today the positive results of the PHERGain trial. This study is the first to use an adaptive design that tailors treatment in the neoadjuvant/adjuvant setting of patients with HER2-positive early breast cancer. The main objective of this trial was to assess the feasibility of a chemotherapy-free strategy based on a dual HER2 blockade with trastuzumab and pertuzumab through a positron emission tomography (PET)-based, pathologic complete response response(pCR)-adapted strategy.
An MD Anderson-led Phase II trial showed the HER2-targeted therapy zanidatamab demonstrated durable responses in patients with advanced HER2-positive biliary tract cancer. The data were presented at the 2023 ASCO Annual Meeting.
A study involving UCLA Jonsson Comprehensive Cancer Center researchers found when ribociclib, a targeted therapy drug, is added to hormone therapy there are significant survival benefits for patients with early hormone-receptor (HR) positive/HER2 negative breast cancer.
A roundup of the latest medical discoveries and faculty news at Cedars-Sinai in May 2023.
The results of a new clinical trial suggest that the first drug therapy to slow the progression of nearsightedness in kids could be on the horizon.
A drug combination that shows little overall survival benefit in white men with advanced prostate cancer has a far greater effect in Black men with the disease, according to interim results from a study led by the Duke Cancer Institute.
The first successful in-patient trial of liver dialysis* has been completed by researchers from UCL, the Royal Free Hospital, UCL spin-out Yaqrit and their collaborators.
Read about new melanoma treatment practices, how models provide information about a rare adrenal cancer, a potential oral medication for brain cancer, and clinical trials for cancer patients with HIV.
Cedars-Sinai Cancer physician-scientists with expertise in liver, skin, lung, breast, colorectal, pancreatic, brain, prostate and endometrial cancers will be attending the American Society of Clinical Oncology annual meeting June 2-6 in Chicago and are available for in-person or virtual interviews to discuss the latest news and research.
A biomarker is a characteristic that can be measured and evaluated as an indicator of normal biological processes, pathogenetic processes, or pharmacologic responses to a therapeutic intervention. In the context of Alzheimer’s disease (AD), an AD biomarker indicates the presence or progression of the disease that may be altered by drug treatment, thereby demonstrating that it is hitting its target. Today, all clinical trials for Alzheimer’s disease utilize biomarkers of some form to assess whether the drug is actually affecting the disease in the brain.
A clinical trial, led by Dana-Farber Cancer Institute, has shown that a telephone-based weight loss program can help patients with breast cancer whose body mass index is in the overweight or obese range lower their weight by a meaningful degree.
Breakthrough study addresses unmet need in the treatment of Crohn’s disease and helps patients into clinical and endoscopic remission
According to the newly released “Alzheimer’s Disease Drug Development Pipeline: 2023,” there are currently 187 clinical trials in the Alzheimer’s drug development pipeline – the most ever on record. This momentum is driven in part by greater investment from the pharma industry and a bump in biologic therapies – particularly monoclonal antibodies – that were central to the success of both recent FDA-approved drugs. The annual report spots trends in clinical trial design and outcome measures, and also investigate the types of agents and biological targets that are being pursued.
The George Institute for Global Health today announced data from the phase III INTERACT3 study demonstrating that a new combination of treatments for stroke due to intracerebral haemorrhage (ICH) significantly improves the chances of surviving without major disability.
Taking a daily multivitamin may help slow age-related memory decline, a study has found.
Experts also available for interviews on trending topics and studies
Unfortunately, effective medical therapies do not exist for this population of patients, Dr. Pavan Bhatraju said. In their paper, the investigators proposed a way to classify subpopulations of AKI patients with the aim of identifying therapies specific patient populations.
Long-awaited outcomes data of transcatheter edge-to-edge procedures to repair patients’ leaky mitral valves revealed the minimally invasive procedure to be safe and effective in nearly 90% of patients, according to Cedars-Sinai physician-scientists.
Researchers at the University of Warwick and The James Cook University Hospital, Middlesbrough have led a clinical trial, funded by the National Institute for Health and Care Research (NIHR), on a new treatment which can help people stop needing to use opioid painkillers to manage chronic pain.
A new device invented with the help of an electrophysiologist at The Ohio State University Wexner Medical Center makes a heart procedure safer for patients suffering from atrial fibrillation (AFib), a common irregular heart rhythm.
Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center will discuss the latest research and clinical trial results on combination therapies for breast cancer, a potential new treatment for patients with recurrent glioma, and advances in PSMA PET guided radiotherapy for patients with prostate cancer, among other topics, at the American Society of Clinical Oncology’s annual meeting.
Results from a new clinical trial found overweight and obese patients with persistent and paroxysmal atrial fibrillation (AF) who lose weight prior to a catheter ablation procedure have improved clinical outcomes.
The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington’s disease, when compared to a placebo, according to a recent international study led by UTHealth Houston researcher Erin Furr Stimming, MD, who served as principal investigator on behalf of the KINECT-HD Huntington Study Group.
Clinical trials offer more than just a chance for patients to become pioneers. While helping the world to get the best care, often study volunteers access the best care for themselves. A Penn State Health expert weighs in.
First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic stents, which are currently the standard treatment for heart disease patients undergoing percutaneous coronary intervention (PCI).
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
